Abstract

Background

Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of the phase 2 INSIGHT 2 study evaluating tepotinib, a highly selective MET inhibitor, combined with osimertinib in this population.

Methods 

This open-label, phase 2 study was conducted at 179 academic centres and community clinics in 17 countries. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1 and advanced or metastatic EGFR-mutated NSCLC of any histology, with MET amplification by tissue biopsy fluorescence in-situ hybridisation (FISH; MET gene copy number of ≥5 or MET-to-CEP7 ratio of ≥2) or liquid biopsy next-generation sequencing (MET plasma gene copy number of ≥2·3), following progression on first-line osimertinib. Patients received oral tepotinib 500 mg plus oral osimertinib 80 mg once daily. The primary endpoint was independently assessed objective response in patients with MET amplification by central FISH treated with tepotinib plus osimertinib with at least 9 months of follow-up. Safety was analysed in patients who received at least one study drug dose. This study is registered with ClinicalTrials.gov, NCT03940703 (enrolment complete).

Findings

Between Feb 13, 2020, and Nov 4, 2022, 128 patients (74 [58%] female, 54 [42%] male) were enrolled and initiated tepotinib plus osimertinib. The primary activity analysis population included 98 patients with MET amplification confirmed by central FISH, previous first-line osimertinib and at least 9 months of follow-up (median 12·7 months [IQR 9·9-20·3]). The confirmed objective response rate was 50·0% (95% CI 39·7-60·3; 49 of 98 patients). The most common treatment-related grade 3 or worse adverse events were peripheral oedema (six [5%] of 128 patients), decreased appetite (five [4%]), prolonged electrocardiogram QT interval (five [4%]), and pneumonitis (four [3%]). Serious treatment-related adverse events were reported in 16 (13%) patients. Deaths of four (3%) patients were assessed as potentially related to either trial drug by the investigator due to pneumonitis (two [2%] patients), decreased platelet count (one [1%]), respiratory failure (one [1%]), and dyspnoea (one [1%]); one death was attributed to both pneumonitis and dyspnoea.

Interpretation

Tepotinib plus osimertinib showed promising activity and acceptable safety in patients with EGFR-mutated NSCLC and MET amplification as a mechanism of resistance to first-line osimertinib, suggesting a potential chemotherapy-sparing oral targeted therapy option that should be further investigated.
 

• Chmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., Todd, A., Markovets, A., Barrett, J. C., Hartmaier, R. J., & Ramalingam, S. S. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications, 14(1), Article 1070. https://doi.org/10.1038/s41467-023-35961-y

• Choudhury, N. J., Marra, A., Sui, J. S. Y., Flynn, J., Yang, S.-R., Falcon, C. J., Selenica, Pier., Schoenfeld, A. J., Rekhtman, N., Gomez, D., Berger, M. F., Ladanyi, M., Arcila, M., Rudin, C. M., Riely, G. J., Kris, M. G., Heller, G., Reis-Filho, J. S., & Yu, H. A. (2023). Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. Journal of Thoracic Oncology, 18(4), 463–475. https://doi.org/10.1016/j.jtho.2022.11.022

• Yu, H. A., Kerr, K., Rolfo, C., & et al. (2023). Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib [Abstract 9074]. Journal of Clinical Oncology, 41(16_suppl).

• National Comprehensive Cancer Network. (2024). Non-small cell lung cancer (Version 3.2024). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

• Mazieres, J., Paik, P. K., Garassino, M. C., & et al. (2023). Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: Long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncology, 9(9), 1260–1266.

• Wu, Y. L., Cheng, Y., Zhou, J., & et al. (2020). Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): An open-label, phase 1b/2, multicentre, randomised trial. The Lancet Respiratory Medicine, 8(11), 1132–1143.

• Liam, C. K., Ahmad, A. R., Hsia, T. C., & et al. (2023). Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis. Clinical Cancer Research, 29(10), 1879–1886.

• Smit, E. F., Dooms, C., Raskin, J., & et al. (2022). INSIGHT 2: A phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncology, 18(9), 1039–1054.

• Jackman, D., Pao, W., Riely, G. J., & et al. (2010). Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology, 28(2), 357–360.

• Lin, N. U., Lee, E. Q., Aoyama, H., & et al. (2015). Response assessment criteria for brain metastases: Proposal from the RANO group. The Lancet Oncology, 16(6), e270–e278.

• Soria, J. C., Wu, Y. L., Nakagawa, K., & et al. (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. The Lancet Oncology, 16(8), 990–998.

• Duncan, D. J., Vandenberghe, M. E., Scott, M. L. J., & et al. (2019). Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer. PLoS One, 14(10), Article e0223926.

• Peng, L., Li, A., Liu, S., & et al. (2021). P85.02 NGS could not replace FISH regarding to MET amplification as an optimal biomarker. Journal of Thoracic Oncology, 16(3), S669.

• Yang, J. C.-H., Lee, D. H., Lee, J.-S., & et al. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study [Abstract LBA9000]. Journal of Clinical Oncology, 41(17_suppl).

• Mok, T., Nakagawa, K., Park, K., & et al. (2024). Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722. Journal of Clinical Oncology, 42(11), 1252–1264.

• Wang, K., Du, R., Roy-Chowdhuri, S., & et al. (2023). Brief report: Clinical response, toxicity, and resistance mechanisms to osimertinib plus MET inhibitors in patients with EGFR-mutant MET-amplified NSCLC. JTO Clinical Research Reports, 4(5), Article 100533.

• Liu, L., Qu, J., Heng, J., & et al. (2021). A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant non-small-cell lung cancer after development of EGFR-TKI resistance. Frontiers in Oncology, 11, Article 722039.

• Reck, M., Mok, T. S. K., Nishio, M., & et al. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. The Lancet Respiratory Medicine, 7(5), 387–401.

• Lu, S., Wu, L., Jian, H., & et al. (2023). Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): Second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, 11(7), 624–636.

• Passaro, A., Wang, J., Wang, Y., & et al. (2024). Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study. Annals of Oncology, 35(1), 77–90.

• Wu, Y.-L., & Zhou, Q. (2023). Combination therapy for EGFR-mutated lung cancer. New England Journal of Medicine, 389(21), 2005–2007.

• Yu, H. A., Goto, Y., Hayashi, H., & et al. (2023). HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. Journal of Clinical Oncology, 41(35), 5363–5375.

• Garon, E. B., Johnson, ML., Lisberg, A. E., & et al. (2021). LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. Annals of Oncology, 32, S1326–S1327.

• Horinouchi, H., Goldman, J. W., Cho, B. C., & et al. (2022). 387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study. Annals of Oncology, 33, S1592.

• Yu, Y., Yang, N., Zhang, Y., & et al. (2022). 305MO SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification. Annals of Oncology, 33, S1553.

• Hartmaier, R. J., Markovets, A. A., Ahn, M. J., & et al. (2023). Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discovery, 13(1), 98–113.

• Ahn, M., De Marinis, F., Bonanno, L., & et al. (2022). EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: Savolitinib+osimertinib in EGFRm NSCLC post-osimertinib. Journal of Thoracic Oncology, 17(9), S469–S470.

• Yu, H. A., Ambrose, H., Baik, C., & et al. (2021). 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Annals of Oncology, 32, S949–S1039.

• Patil, T., Staley, A., Nie, Y., & et al. (2024). The efficacy and safety of treating acquired MET resistance through combinations of parent and MET tyrosine kinase inhibitors in patients with metastatic oncogene-driven NSCLC. JTO Clinical Research Reports, 5(2), Article 100637.

• Nagasaka, M., Balmanoukian, A. S., Madison, R., & et al. (2022). Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/T790M/G796S) in cis. Lung Cancer, 164, 52–55.

• Gillespie, C. S., Mustafa, M. A., Richardson, G. E., & et al. (2023). Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: A systematic review and meta-analysis. Journal of Thoracic Oncology, 18(12), 1703–1713.

• Friese-Hamim, M., Clark, A., Perrin, D., & et al. (2022). Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases. Lung Cancer, 163, 77–86.

• Soria, J. C., Ohe, Y., Vansteenkiste, J., & et al. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113–125.

• Planchard, D., Jänne, P. A., Cheng, Y., & et al. (2023). Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. New England Journal of Medicine, 389(21), 1935–1948.